Equity Research on Forest Laboratories Inc. and Endo Health Solutions Inc. - Patent Expiries and New Releases Lead to Mixed R...
July 30 2012 - 8:20AM
Marketwired
www.StockCall.com offers free research on
Forest
Laboratories Inc. (NYSE: FRX) and
Endo Health
Solutions Inc. (NASDAQ: ENDP) from the Drug Manufacturers -
Other industry. Access these reports by clicking on the links below
or by copy and pasting those to your address bar.
www.StockCall.com/reports
The drug manufacturers industry, which features companies such
as Forest Laboratories Inc. and Endo Health Solutions Inc.
continues to be negatively impacted by patent expirations. Several
major brand-name drugs have lost exclusivity as of late, and the
results are appearing on company financials.
StockCall.com is an online platform where investors doing their
due-diligence on the Drug Manufacturers - Other industry can have
easy and free access to our analyst research and opinions on Forest
Laboratories Inc. and Endo Health Solutions Inc. To see how
companies in this industry have grown over the past years and how
they are expected to perform in the future, please visit the link
below.
www.StockCall.com
In the case of Forest Laboratories, the company recently
reported that earnings from its fiscal 1st quarter came in at $55.3
million, down substantially from earnings of $258.1 million
achieved during the same quarter last year. One reason for the
decline was the loss of exclusivity for Lexapro. Endo Health has
also been dealing with challenges stemming from losses of
exclusivity. Register now to have free access to our report on Endo
Health Solutions Inc., and to do so please click the link
below.
www.StockCall.com/ENDP300712.pdf
In an attempt to improve sales and grow revenues, companies in
the industry have been working hard on releasing new products.
Forest Laboratories together with Almirall S.A. have recently had
success in this regard, stating that the FDA has approved Tudorza™
Pressair™ for the treatment of Bronchospasm associated with chronic
obstructive pulmonary disease. Investors and shareholders of Forest
Laboratories Inc. can simply register for our complimentary reports
by clicking on the link below.
www.StockCall.com/FRX300712.pdf
About StockCall.com
StockCall.com is a financial website where investors can have
easy, precise and comprehensive research and opinions on stocks
making the headlines.
Contact Person: William T. Knight
stockcall2010@gmail.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024